olivLaw · US equity research
Ainos, Inc. AIMD
Computer Peripheral Equipment, NEC · SIC 3577 · Vertical: Computer Peripheral Equipment, NEC (SIC 3577)
Ainos is a dual-platform company developing the AI Nose AI-based smell sensor and the VELDONA® oral interferon therapy. The company is at an early stage of commercializing AI Nose in industry, with revenue still very small against large operating losses and a tight cash position, around and million dollars.
At the close of 04 Nov 2026, Ainos, Inc. (AIMD) stock was 0.73 USD (+17.74% on the day), with market capitalisation 5.4 m USD, beta 1.66, 52-week range 0.62–3.26 USD. Latest reported quarter (Q2 2026): revenue of 152 USD (−96.7% YoY), net income of -4.6 m USD, diluted EPS -0.62 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 31.0
- weak (30–45)
- Bollinger (20, 2)
- 0.53 – 1.23
- in the lower half of the band · %B 0.29 · band width 79.5%
- SMA 50 / 200
- 1.20 / 1.58
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.16 / -0.15
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −45.1% | −1.1% | −44.0 pp | — |
| 3 months | −48.6% | −0.5% | −48.1 pp | — |
| 6 months | −58.8% | +4.4% | −63.1 pp | — |
| Year to date | −55.5% | +12.3% | −67.8 pp | — |
| 1 year | −77.7% | +13.5% | −91.3 pp | −9.7% |
| 3 years | −95.1% | +76.4% | −171.5 pp | +6.8% |
| 5 years | −99.5% | +63.7% | −163.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 ≈ | 0 | 106.2 k | 4.7 k | 2.2 k | 11.1 k | 161 | 152 |
| Cost of revenue | 547 | -79 | 18.2 k | 937 | 477 | 1.6 k | 763 | 53 |
| Gross profit | -547 | 79 | 88.0 k | 3.7 k | 1.7 k | 9.5 k | -602 | 99 |
| Research & development | 2.0 m | 2.3 m | 1.7 m | 1.9 m | 2.0 m | 2.1 m | 1.7 m | 1.9 m |
| SG&A | 1.0 m | 2.3 m | 1.5 m | 1.8 m | 795.3 k | 2.2 m | 593.2 k | 2.5 m |
| Operating income | -3.0 m | -4.6 m | -3.2 m | -3.7 m | -2.8 m | -4.3 m | -2.3 m | -4.4 m |
| Depreciation & amortisation | 1.2 m ≈ | 1.2 m | 1.2 m | 1.2 m ≈ | 1.2 m ≈ | 1.2 m | 1.2 m | 1.2 m ≈ |
| Interest expense | 264.6 k | 184.4 k | 180.4 k | 178.0 k | 176.6 k | 176.9 k | 176.9 k | 200.2 k |
| Pre-tax income | -3.7 m | -4.7 m | -3.3 m | -4.1 m | -2.9 m | -4.5 m | -2.5 m | -4.6 m |
| Net income | -3.7 m | -4.7 m | -3.3 m | -4.1 m | -2.9 m | -4.5 m | -2.5 m | -4.6 m |
| Diluted EPS | -1.64 | -1.62 ≈ | -1.04 | -0.99 | -0.64 | -0.86 ≈ | -0.41 | -0.62 |
| Operating cash flow | -1.5 m ≈ | -864.2 k | -1.2 m | -1.4 m ≈ | -1.2 m ≈ | -855.0 k | -983.4 k | -1.4 m ≈ |
| Capex | 10.1 k ≈ | 908 | 33.6 k | -7.7 k ≈ | 10.1 k ≈ | -1.5 k | 8.5 k | 5.8 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 77.7 k | 11.7 k | 16.6 k | 594.6 k | 3.5 m | 122.1 k | 20.7 k | 124.2 k |
| Revenue YoY | −69.0% | −84.9% | +41.2% | +3,489.7% | +492.0% | −96.5% | −83.0% | +499.0% |
| Net income | -1.3 m | -1.6 m | -1.5 m | -3.9 m | -14.0 m | -13.8 m | -14.9 m | -14.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | unavailable | -3.36 | -7.82 | -3.46 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -1,722.3% | -13,479.7% | -8,758.2% | -654.0% | -398.0% | -11,277.0% | -71,702.3% | -11,897.0% |
| Free cash flow | -1.0 m | -911.1 k | -499.6 k | -1.4 m | -3.7 m | -4.8 m | -5.8 m | -4.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 417.4 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 7.6 m USD
- Total assets
- 20.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.06x
- ROE
- -128.0%
- ROA
- -59.5%
- FCF margin
- -3,744.7%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 16.6 k | 594.6 k | 3.5 m | 122.1 k | 20.7 k | 124.2 k | SEC (XBRL)· 30 Mar 2026verified |
| Cost of revenue | 11.3 k | 184.2 k | 2.1 m | 375.8 k | 52.6 k | 21.2 k | SEC (XBRL)· 30 Mar 2026verified |
| Gross profit | 5.3 k | 410.4 k | 1.4 m | -253.7 k | -31.9 k | 102.9 k | SEC (XBRL)· 30 Mar 2026verified |
| Research & development | 389 | 1.9 m | 6.8 m | 7.3 m | 8.4 m | 7.7 m | SEC (XBRL)· 30 Mar 2026verified |
| SG&A | 1.4 m | 2.4 m | 8.5 m | 5.6 m | 5.4 m | 6.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Operating income | -1.4 m | -3.9 m | -14.0 m | -13.2 m | -13.8 m | -14.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Depreciation & amortisation | 14.7 k | 2.0 m | 4.8 m | 4.9 m | 4.8 m | 4.8 m | SEC (XBRL)· 30 Mar 2026verified |
| EBITDA | -1.4 m ≈ | -1.8 m ≈ | -9.1 m ≈ | -8.3 m ≈ | -9.0 m ≈ | -9.2 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Interest expense | 10.7 k | 18.7 k | 53.5 k | 144.2 k | 616.5 k | 711.9 k | SEC (XBRL)· 30 Mar 2026verified |
| Pre-tax income | -10.2 k | -21.2 k | -14.0 m | -13.8 m | -14.9 m | -14.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | 0 | — | 0 | 800 | 800 | 800 | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -1.5 m | -3.9 m | -14.0 m | -13.8 m | -14.9 m | -14.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | — | — | — | -3.36 | -7.82 | -3.46 | SEC (XBRL)· 30 Mar 2026verified |
| Weighted average diluted shares | — | — | — | 4.1 m | 1.9 m | 4.3 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 22.2 k | 1.8 m | 1.9 m | 1.9 m | 3.9 m | 417.4 k | SEC (XBRL)· 30 Mar 2026verified |
| Receivables | 0 | 0 | 201.5 k | 455 | 56 | 22 | SEC (XBRL)· 30 Mar 2026verified |
| Inventories | 0 | 0 | 595.2 k | 167.6 k | 143.8 k | 295.6 k | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 76.4 k | 2.2 m | 2.8 m | 2.5 m | 4.3 m | 1.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 3.2 k | 1.2 m | 1.4 m | 876.6 k | 559.6 k | 343.3 k | SEC (XBRL)· 30 Mar 2026verified |
| Intangibles (excl. goodwill) | 180.6 k | 37.3 m | 32.8 m | 28.3 m | 23.7 m | 19.2 m | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 260.3 k | 40.8 m | 37.1 m | 31.8 m | 28.8 m | 20.9 m | SEC (XBRL)· 30 Mar 2026verified |
| Accounts payable | 145.6 k | — | — | — | — | — | SEC (XBRL)· 30 Mar 2021verified |
| Current liabilities | 1.1 m | 30.6 m | 2.5 m | 1.3 m | 4.0 m | 1.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Total liabilities | 1.1 m | 30.6 m | 2.5 m | 7.4 m | 13.3 m | 13.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | -838.3 k | 10.2 m † | 34.6 m † | 24.4 m † | 15.5 m † | 7.6 m † | SEC (XBRL)· 30 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -499.6 k | -1.2 m | -3.0 m | -4.7 m | -5.8 m | -4.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 0 | 143.8 k | 633.8 k | 93.0 k | 21.3 k | 34.6 k | SEC (XBRL)· 30 Mar 2026verified |
| Free cash flow | -499.6 k ≈ | -1.4 m ≈ | -3.7 m ≈ | -4.8 m ≈ | -5.8 m ≈ | -4.6 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Investing cash flow | -7.2 k | -180.5 k | -630.2 k | -101.5 k | -125.3 k | -2.2 k | SEC (XBRL)· 30 Mar 2026verified |
| Financing cash flow | 120.0 k | 3.2 m | 3.9 m | 4.9 m | 8.0 m | 1.0 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
4 indicators that do not apply to the sector.
Valuation
olivLaw classification
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 5.4 m USD
Key indicators
Coverage and freshness
Score by group
72% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/Salesunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| Gross margin · Quality | 78.7% | 97 (on a fixed band) | 15% |
| EBIT margin · Quality | -101,210.2% | 0 (vs peers) | 12% |
| FCF margin · Quality | -33,046.9% | 0 (on a fixed band) | 12% |
| Revenue CAGR 3Y · Growth | -67.2% | 0 (on a fixed band) | 24% |
| Revenue growth (YoY) · Growth | 499.0% | 100 (vs peers) | 12% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.1x | 0 (on a fixed band) | 9% |
| EV/Sales · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -83.4% | 0 (on a fixed band) | 18% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial0/100 · 1/2 factors with a value
- Growth33/100 · 2/2 factors with a value
- Quality37/100 · 3/3 factors with a value
- Returns· partialunavailable · 0/1 factors with a value
- Valuation· partial0/100 · 1/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
AINOS, INC. (AIMD). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 124.2 k USD in 2025; YoY growth 499.0%; net margin -106,283.3%; ROE -196.3%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Gross margin: 78.7%
- Revenue growth (YoY): 499.0%
What contradicts it
- EBIT margin: -101,210.2%
- FCF margin: -33,046.9%
- Revenue CAGR 3Y: -67.2%
- Current ratio: 0.1x
- FCF yield: -83.4%
Not assessed (insufficient data or a ratio without meaning): Net debt / EBITDA, EV/Sales, Shareholder yield (distributions).
Versus the vertical median
Computer Peripheral Equipment, NEC (SIC 3577) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| PANWPalo Alto Networks, Inc. | 284.7 bn | 870.1 | 1.7% | 2.7% | +24.5% | +83% / +136% |
| FTNTFortinet, Inc. | 95.1 bn | 42.1 | 153.1% | 29.0% | +14.2% | +59% / +146% |
| LOGILogitech International S.A. | 14.2 bn | 18.1 | 38.2% | 16.4% | +6.3% | −11% / +14% |
| CRSRCorsair Gaming, Inc. | 1.4 bn | 41.4 | 5.8% | 2.5% | +11.9% | +104% / +3% |
| EVLVEvolv Technologies Holdings, Inc. | 871.2 m | — | -4.9% | -3.0% | +40.5% | −25% / +20% |
| MITKMitek Systems, Inc. | 861.4 m | 40.7 | 9.2% | 11.4% | +4.4% | +115% / +69% |
| SSYSStratasys Ltd. | 587.3 m | — | -12.7% | -18.9% | −3.7% | −22% / −38% |
| IMMRImmersion Corporation | 237.8 m | 21.6 | 3.5% | 0.6% | +11.2% | +1% / +10% |
| RDCMRadcom Ltd. | 168.7 m | 14.3 | 11.4% | 16.8% | +17.2% | −22% / +29% |
| XRXXerox Holdings Corp | 155.0 m | — | -128.0% | -11.9% | +12.9% | −58% / −92% |
| MYNDMynd.ai, Inc. | 126.0 m | — | -995.5% | -32.2% | −37.2% | −56% / −97% |
| INVEInve Technologies, Inc. | 64.0 m | — | -10.9% | -62.9% | −19.3% | −22% / −62% |
| TACTTransact Technologies Inc | 54.4 m | — | -1.3% | -0.8% | +18.7% | +19% / −22% |
| LINKInterlink Electronics, Inc | 52.3 m | — | -10.5% | -7.9% | +1.8% | −8% / −39% |
| WETHWetouch Technology Inc. | 11.6 m | 1.2 | 6.0% | 17.6% | +6.8% | −57% / unavailable |
| AIMDAinos, Inc. | 5.4 m | — | -196.3% | -106,283.3% | +499.0% | −78% / −95% |
| VTIXVirtuix Holdings Inc. | — | — | — | -543.2% | +18.4% | unavailable / unavailable |
| YIBOPlanet Image International Limited | — | — | -14.4% | -5.3% | +3.6% | +5% / unavailable |
1- and 3-year price returns: for AIMD from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Ainos is a dual-platform company developing the AI Nose AI-based smell sensor and the VELDONA® oral interferon therapy. The company is at an early stage of commercializing AI Nose in industry, with revenue still very small against large operating losses and a tight cash position, around 1 and 2 million dollars.
SWOT
Strengths
- The AI Nose platform has a large volume of proprietary data from industrial deployments, which the company uses to improve its models 3.
- The company has won a multi-year industrial commercial contract with a semiconductor packaging customer 1.
- The operating model outsources manufacturing and concentrates research in Taiwan, which keeps fixed costs lower 1.
Weaknesses
Opportunities
- If robotics and hospital infrastructure pilots turn into commercial contracts, revenue could grow 13.
- Out-licensing partnerships for VELDONA® could bring funding without a large use of the company's own cash 1.
- The SmellTech-as-a-Service model could generate recurring revenue after hardware installation 3.
Risks
- Lack of significant revenuehigh
The company has not yet generated revenue sufficient to cover operating costs, and profitability is uncertain 1.
- Need for additional fundinghigh
If funding cannot be obtained on acceptable terms, development programs could be scaled back or stopped 1.
- Higher indebtednesshigh
The sharp rise in current liabilities in the first half of 2026 may limit financial flexibility 2.
- Component supplymedium
Disruptions in the supply chain could delay deployments and increase costs 2.
- Regulation and certificationmedium
Approvals for medical and radio devices may delay commercialization in several countries 1.
Investment thesis
What would need to be true (bull case)
- If semiconductor and robotics pilots turn into broader commercial contracts, AI Nose revenue could rise quickly from its current level.
- A large volume of deployment data could improve model performance and strengthen the platform's position.
- Out-licensing partnerships for VELDONA® could bring revenue without requiring significant additional funding.
What would break the thesis
- Revenue has remained very small, and large operating losses could continue if commercial adoption is delayed.
- Growing current liabilities and limited available capital could force dilution or restructuring.
- Dependence on partners and regulatory approvals could slow the whole commercialization plan.
What to watch
- Revenue in the second half of 2026 and conversion of pilots into contracts2026
- Development of current liabilities and available cashQ3 2026
- Progress of industrial contracts and VELDONA® out-licensing partnerships2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Ainos, Inc., incorporated in Texas in 1984, focuses on the AI Nose platform, an electronic olfaction system that converts scent and volatile organic compound signals into structured data called Smell ID, using gas sensor arrays and an artificial intelligence model called a smell language model. The company started from point-of-care healthcare applications and expanded toward industrial environments such as semiconductor manufacturing, robotics and smart manufacturing 1. In parallel it develops VELDONA®, a low-dose oral interferon formulation with clinical studies in Taiwan, while manufacturing is outsourced and research and operations are concentrated in Taiwan 1.
In fiscal 2025 revenue was only 124,157 dollars, almost all from AI Nose, and the operating loss was 13,990,408 dollars 1. The company had 41 full-time employees as of December 31, 2025 1. The business model combines AI Nose hardware with recurring services, particularly subscription-based SmellTech-as-a-Service offerings, described in the August 2026 release 3.
Segments
VELDONA® (low-dose oral interferon)
VELDONA® includes candidates for oral warts in HIV-positive patients, Sjögren's syndrome and feline chronic gingivostomatitis, with clinical studies in Taiwan. The company intends to seek out-licensing partners, and a pet supplement was launched in Taiwan with limited sales 1.
Market context
AI Nose positions itself in the markets for environmental sensing and volatile organic compound detection, where industrial applications in semiconductors, robotics and hospital infrastructure are at pilot stage or in first commercial orders 13. The market size is not quantified in the sources provided, and adoption depends on converting pilots into larger contracts.
In immune therapeutics, VELDONA® competes in rare and autoimmune niches, where clinical data and partnerships define value. The sources give no market figures for these niches, so the assessment remains qualitative.
Competitive position
The sources provided do not explicitly name direct competitors to AI Nose or VELDONA®. The company mentions partners and distributors such as Inabata and Topco Scientific, but these are commercial partners rather than competitors 1.
The filing describes competition as a general pressure: delays or technological developments by rivals can affect results expectations, and industry consolidation is a named factor 1.
- Distribution and integration partners in Asia (Inabata, Topco Scientific)
Named in the filing as commercial partners for product commercialization, not as direct competitors.
- Gas sensor manufacturers (as a category)
The sources contrast conventional gas sensors with AI Nose, which is positioned as a connected and trainable platform 1.
- Companies with industrial sensor platforms
The sources do not name specific competitors in this category, so they cannot be identified from the documents.
- Other interferon and immune therapy developers
The sources mention general competition in immune therapeutics without naming companies with tickers.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report16 Oct 2026Amendments to articles or bylaws · Other events · Financial statements and exhibits
- Current report28 Sept 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report03 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report03 Aug 2026
- Current report10 Jul 2026Item 4.01 · Financial statements and exhibits
- Current report09 Jul 2026Creation of a direct financial obligation · Financial statements and exhibits
- Quarterly report13 May 2026
- Current report13 May 2026Results of operations · Financial statements and exhibits
- Annual report30 Mar 2026
- Current report30 Mar 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Ainos, Inc. · 30 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Ainos, Inc. · 03 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Ainos, Inc. · 03 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.